Elise F Nassif, MD, MS
Department of Sarcoma Center, Division of VP Ambulatory Operations
About Dr. Elise F Nassif
I am a physician-scientist in the Department of Sarcoma Medical Oncology. I received my medical degree in 2014 and my medical oncology specialty in 2020 from Paris University (France). During my residency and fellowship in France, I trained at Gustave Roussy Cancer Center and completed a master of science in Immunology in 2019. After completion of my clinical training, I pursued a research post-doctoral fellowship at MD Anderson during two years, focusing on characterizing the immune microenvironment of sarcomas and identifying new immune therapeutic targets to improve sarcoma care. I have a particular interest in the care of patients with leiomyosarcomas and undifferentiated pleomorphic sarcomas. My main research focus are leiomyosarcomas, undifferentiated pleomorphic sarcomas, i mmunotherapy, and drug development in sarcomas.
Read More
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2019 | Université Paris Descartes, Paris, FRA, MS, Immunology |
| 2014 | Université Paris Descartes, Paris, FRA, MD, Medicine |
Postgraduate Training
| 2021-2022 | Research Fellowship, Translational immuno-oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2014-2020 | Clinical Fellowship, Medical Oncology, Université Paris Descartes, Paris |
| 2014-2020 | Clinical Residency, Université Paris Descartes, Paris |
Honors & Awards
| 2022 | Daniel Benedict Gazan Award in Sarcoma Research, The University of Texas MD Anderson Cancer Center |
| 2022 | GlaxoSmithKline Endowed Merit Award, ASCO / Conquer Cancer |
| 2021 | Travel Award, European Society for Medical Oncology |
| 2020 | Young Investigator Award, American Radium Society |
Selected Publications
Peer-Reviewed Articles
- Erstad DJ, Chiang YJ, Witt RG, Cope B, Nassif EF, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. Ann Surg Oncol 30(2):926-940, 2023. e-Pub 2022. PMID: 36115928.
- Torregrosa C, Pernot S, Vaflard P, Perret A, Tournigand C, Randrian V, Doat S, Neuzillet C, Moulin V, Stouvenot M, Roth G, Darbas T, Auberger B, Godet T, Jaffrelot M, Lambert A, Dubreuil O, Gluszak C, Bernard-Tessier A, Turpin A, Palmieri LJ, Bouche O, Goujon G, Lecomte T, Sefrioui D, Locher C, Grados L, Gignoux P, Trager S, Nassif E, Saint A, Hammel P, Lecaille C, Bureau M, Perrier M, Botsen D, Bourgeois V, Taieb J, Auclin E. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Int J Cancer 151(11):1978-1988, 2022. e-Pub 2022. PMID: 35833561.
- Witt RG, Cope B, Erstad DJ, Chiang YJ, Nassif EF, Scally CP, Torres KE, Hunt KK, Feig BW, Roland CL, Keung EZ. Sentinel Lymph Node Biopsy and Formal Lymphadenectomy for Soft Tissue Sarcoma: A Single Center Experience of 86 Consecutive Cases. Ann Surg Oncol 29(11):7092-7100, 2022. e-Pub 2022. PMID: 35501583.
- Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol 23(9):1156-1166, 2022. e-Pub 2022. PMID: 35934010.
- Nassif EF, Cope B, Traweek R, Witt RG, Erstad DJ, Scally CP, Thirasastr P, Zarzour MA, Ludwig J, Benjamin R, Bishop AJ, Guadagnolo BA, Ingram D, Wani K, Wang WL, Lazar AJ, Torres KE, Hunt KK, Feig BW, Roland CL, Somaiah N, Keung EZ. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer 150(12):2012-2024, 2022. e-Pub 2022. PMID: 35128664.
- Nassif EF, Blay JY, Massard C, Dufresne A, Brahmi M, Cassier P, Ray-Coquard I, Pautier P, Leary A, Sunyach MP, Bahleda R, Levy A, Le Pechoux C, Honoré C, Mir O, Le Cesne A. Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials. ESMO Open 7(2):100425, 2022. e-Pub 2022. PMID: 35255445.
- Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ*, Nassif EF*. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol 12:1008484, 2022. e-Pub 2022. PMID: 36313661.
- Traweek RS, Cope BM, Roland CL, Keung EZ, Nassif EF, Erstad DJ. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma. Front Oncol 12:1006959, 2022. e-Pub 2022. PMID: 36439412.
- Nassif EF, Auclin E, Bahleda R, Honoré C, Mir O, Dumont S, Mery B, Hodroj K, Brahmi M, Trédan O, Ray-Coquard I, Blay JY, Massard C, Le Cesne A, Dufresne A. TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials. Cancers (Basel) 13(13), 2021. e-Pub 2021. PMID: 34282771.
- Nassif EF, Maloney N, Conley AP, Keung EZ. Disseminated Coccidioidomycosis Following COVID-19 Mimicking Metastatic Thoracic Relapse of Well-Differentiated Liposarcoma: A Case Report. Front Med (Lausanne) 8:715939, 2021. e-Pub 2021. PMID: 34589500.
- Roulleaux Dugage M*, Nassif EF*, Italiano A, Bahleda R. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Front Immunol 12:775761, 2021. e-Pub 2021. PMID: 34925348.
- Nassif EF, Mlecnik B, Thibault C, Auvray M, Bruni D, Colau A, Compérat E, Bindea G, Catteau A, Fugon A, Boquet I, Martel M, Camparo P, Colin P, Zakopoulou R, Bamias A, Bennamoun M, Barthere X, D'acremont B, Lefevre M, Audenet F, Mejean A, Verkarre V, Oudard S, Galon J. The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival. Cancers (Basel) 13(3), 2021. e-Pub 2021. PMID: 33525361.
- Boilève A, Dufresne A, Chamseddine A, Nassif E, Dumont S, Brahmi M, Adam J, Rouleau E, Karanian M, Haddad V, Faron M, Honoré C, Meeus P, Le Cesne A, Blay JY, Mir O. Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment. ESMO Open 5(6):e001082, 2020. PMID: 33246932.
- Honoré C, Delhorme JB, Nassif E, Faron M, Ferron G, Bompas E, Glehen O, Italiano A, Bertucci F, Orbach D, Pocard M, Quenet F, Blay JY, Carrere S, Chevreau C, Mir O, Le Cesne A, French Network for Rare Peritoneal Malignancies (RENAPE), French Sarcoma Clinical Network (NETSARC). Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients. Surg Oncol 29:107-112, 2019. e-Pub 2019. PMID: 31196472.
- Nassif EF, Arsène-Henry A, Kirova YM. Brain metastases and treatment: multiplying cognitive toxicities. Expert Rev Anticancer Ther 19(4):327-341, 2019. e-Pub 2019. PMID: 30755047.
- Nassif E, Thibault C, Vano Y, Fournier L, Mauge L, Verkarre V, Timsit MO, Mejean A, Tartour E, Oudard S. Sunitinib in kidney cancer: 10 years of experience and development. Expert Rev Anticancer Ther 17(2):129-142, 2017. e-Pub 2016. PMID: 27967249.
- Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. e-Pub 2022. PMID: 36151848.
Invited Articles
- Nassif EF, Thibault C, Oudard S, Galon J. Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer. Oncoimmunology 10(1):1888488, 2021. e-Pub 2021. PMID: 33659099.
Letters to the Editor
- Nassif EF, Roland CL, Keung EZ. Reflections on the value of multidisciplinary oncology training by a medical oncologist. Eur J Surg Oncol.
Grant & Contract Support
| Title: | Identifying Biomarker-Based Immune Targets in Molecular Subtypes of Leiomyosarcomas |
| Funding Source: | Leiomyosarcoma SPORE |
| Role: | Principal Investigator |
| Title: | Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas with B-Cell Receptors |
| Funding Source: | QuadW Foundation |
| Role: | Principal Investigator |